Trial Profile

Single-arm, Open-label, Multicenter Phase Ib Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TQB-2858 (Primary)
Indications Adenocarcinoma; Chondrosarcoma; Ewing's sarcoma; Liposarcoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma
Focus Therapeutic Use
Sponsors Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical

Most Recent Events

19 Jan 2024 Status changed from not yet recruiting to discontinued based on the current clinical research status of dual antibody drugs and full communication with the investigators.
08 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com